NCT05459129View on ClinicalTrials.gov

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

DRUG

Tiragolumab

Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.

DRUG

Carboplatin

Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.

DRUG

Paclitaxel

Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.

Trial Locations (6)

15213

University of Pittsburgh Medical Center, Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

91010

City of Hope, Duarte

9112001

Hadassah University Hospital - Ein Kerem, Jerusaelm

03722

Severance Hospital - Yonsei Cancer Center, Seoul

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY